ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia

Por Perrotti, D, Neviani, P
Publicado em 2006

Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target

Por Harb, J.G., Neviani, P., Chyla, B.J., Ellis, J.E., Ferenchak, G.J., Oaks, J.J., Walker, C. J., Hokland, P., Roy, DC, Caligiuri, M.A., Marcucci, G., Huettner, C.S., Perrotti, D.
Publicado em 2013

Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia

Por Khalife, J, Radomska, HS, Santhanam, R, Huang, X, Neviani, P, Saultz, J, Wang, H, Wu, Y-Z, Alachkar, H, Anghelina, M, Dorrance, A, Curfman, J, Bloomfield, CD, Medeiros, BC, Perrotti, D, Lee, LJ, Lee, RJ, Caligiuri, MA, Pichiorri, F, Croce, CM, Garzon, R, Guzman, ML, Mendler, JH, Marcucci, G
Publicado no Leukemia (2015)